Literature DB >> 15829406

Monoclonal ribosomal P autoantibody inhibits the expression and release of IL-12, TNF-alpha and iNOS in activated RAW macrophage cell line.

Kuang-Hui Sun1, Shye-Jye Tang, Chau-Yaun Chen, Tai-Ping Lee, Chi-Kuang Feng, Chia-Li Yu, Guang-Huan Sun.   

Abstract

Monoclonal ribosomal P protein antibody (anti-P mAb) may bind to the cell surface, penetrate into cells, and induce apoptosis of Jurkat T cells. Recently, modulation of cytokines has been considered to be important in the pathogenesis of systemic lupus erythematous (SLE). In this study, effects of anti-P mAbs (9B6) on gene expression of cytokines, apoptosis, and reactive oxygen species in murine macrophage RAW 264.7 were analyzed by RT-PCR and ELISA and those on IL-12 promoter activity was determined in an IL-12p40 promoter-reporter gene transfected cell line RAW (IL-12p40-SEAP). After treating LPS-activated RAW 264.7 with 9B6 for 6 or 24 h, the levels of mRNA and protein expression of IL-12, TNF-alpha, and iNOS were significantly inhibited by 25%, 16%, and 13%, respectively. The IL-12 promoter activity of RAW (IL-12p40-SEAP) was also inhibited by 13-22%. However, inhibitory effects were not observed in cells pre-treated with IgG1 for 1 h. The productions of IL-10 in LPS-activated RAW 264.7 and human macrophages were potentiated by 9B6 up to 65% and 51%, respectively. Since anti-P Abs inhibit productions of IL-12 and TNF-alpha and enhance IL-10 production in macrophages, these autoantibodies may augment Th2 responses and amplify lupus manifestations by causing immunological polarity and lymphocyte dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829406     DOI: 10.1016/j.jaut.2005.01.002

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus.

Authors:  Wanling Yang; Nan Shen; Dong-Qing Ye; Qiji Liu; Yan Zhang; Xiao-Xia Qian; Nattiya Hirankarn; Dingge Ying; Hai-Feng Pan; Chi Chiu Mok; Tak Mao Chan; Raymond Woon Sing Wong; Ka Wing Lee; Mo Yin Mok; Sik Nin Wong; Alexander Moon Ho Leung; Xiang-Pei Li; Yingyos Avihingsanon; Chun-Ming Wong; Tsz Leung Lee; Marco Hok Kung Ho; Pamela Pui Wah Lee; Yuk Kwan Chang; Philip H Li; Ruo-Jie Li; Lu Zhang; Wilfred Hing Sang Wong; Irene Oi Lin Ng; Chak Sing Lau; Pak Chung Sham; Yu Lung Lau
Journal:  PLoS Genet       Date:  2010-02-12       Impact factor: 5.917

2.  Anti-ribosomal phosphoprotein autoantibody triggers interleukin-10 overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways in lipopolysaccharide-activated macrophages.

Authors:  Tai-Ping Lee; Shr-Jeng Jim Leu; Jason C Huang; Ying-Chyi Song; Ren-Shiang Jhou; Shye-Jye Tang; Kuang-Hui Sun
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

Review 3.  Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management.

Authors:  Julia J Rhiannon
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 4.  Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?

Authors:  Emese Kiss; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

5.  Personalized therapy design for systemic lupus erythematosus based on the analysis of protein-protein interaction networks.

Authors:  Elizabeth J Brant; Edward A Rietman; Giannoula Lakka Klement; Marco Cavaglia; Jack A Tuszynski
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.